New research from Dr. Helen Tremlett’s Pharmacoepidemiology in Multiple Sclerosis Research Group suggests that for people with multiple sclerosis (MS), the presence of psychiatric comorbidities including depression, anxiety and mood disorders was associated with disability progression.
You are hereNews & Events
People who live in areas where they are exposed to more of the sun's rays, specifically UV-B rays, may be less likely to develop multiple sclerosis (MS) later in life, according to a study published in today in the journal Neurology. Exposure in childhood and young adulthood may also reduce risk.
Pictured: The Honourable Jody Wilson-Raybould (third from left), Minister of Justice and Member of Parliament, visits Dr. Cheryl Wellington's lab on a tour of DMCBH on October 13, 2017. Image credit: Paul Joseph.
Until now, researchers studying multiple sclerosis (MS) in mouse models have relied on models heavily weighted towards processes secondary to an autoimmune trigger. While discoveries made through these models have informed later translational research and clinical trials to improve drug treatment for people living with MS, a lack of a model for the unique biological process by which the disease progresses in the brain has been challenging.
In Grade 10, fifteen- and sixteen-year-olds begin making the academic decisions that may shape their lives, opting for electives in the sciences or the arts. What they choose will influence where they plan to go to university, what they plan to study, and who they ultimately become.
There are more than ten different drug therapies approved in Canada to treat multiple sclerosis (MS), but what do we know about their long-term value? With a $1.2 million endorsement from CIHR, Dr. Helen Tremlett, Canada Research Chair in Neuroepidemiology and Multiple Sclerosis and her team, will determine the safety and effectiveness of commonly prescribed MS drugs.
For people with multiple sclerosis (MS), the presence of comorbidities—chronic conditions in addition to the primary diagnosis of MS—can affect the risk of relapse and disability progression. Two new papers involving Dr. Helen Tremlett’s team look at comorbidities from two distinct angles, providing new insight into how people living with MS are affected by additional chronic conditions.
Diseases and injuries of the brain have a magnetic quality that can indicate the degree of damage to the brain. For physicist and brain health researcher Dr. Alex Rauscher, making sense of the brain’s magnetic field is a complex equation, but one with the promise to objectively measure deterioration and tissue repair.
“Based on data from a survey we produced last year, 80 per cent of Canadian Principal Investigators (PIs) have indicated plans to slow their research programs,” says Dr. Liisa Galea. “They’re worried about how they’re going to support new trainees, and funding is their primary concern.”